Evidence map›Paper›PMID 38827121›Full record

ArticleInternational journal of particle therapy2024

Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.

Robert W Gao, Jiasen Ma, Thomas M Pisansky, Jon J Kruse, Bradley J Stish, Roman O Kowalchuk, Brendan P McMenomy, Mark R Waddle, Ryan M Phillips, Richard Choo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Robert W GaoDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jiasen MaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Thomas M PisanskyDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jon J KruseDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Bradley J StishDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Roman O KowalchukDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Brendan P McMenomyDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Mark R WaddleDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Ryan M PhillipsDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Richard ChooDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Brian J DavisDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To report clinical and dosimetric characteristics of 5-fraction stereotactic ablative radiotherapy (SABR) using intensity modulated proton therapy (IMPT) for localized prostate cancer. Materials and Methods: All patients receiving IMPT SABR from 2017 to 2021 for localized prostate cancer at our institution were included. Five fractions were delivered every other day to the prostate +/- seminal vesicles [clinical target volume (CTV)] with 3 mm/3% robustness. A 4-field arrangement with 2 anterior oblique and 2 opposed lateral beams was used in most patients (97%), and most (99%) had a retroprostatic hydrogel spacer. Results: A total of 534 patients with low (14%), favorable intermediate (45%), unfavorable intermediate (36%), high (4.0%), or very high-risk (0.6%) disease are evaluated. Prescription dose was 36.25 Gy (31%), 38 Gy (38%), or 40 Gy (31%) was prescribed. Median volume percentage of CTV receiving at least 100% of prescription dose [V100% (%)] was 100% [interquartile range: 99.99-100]. Rectum V50% (%), V80% (%), and V90% (%) were significantly lower in patients who had spacer, with a mean difference of -9.70%, -6.59%, and -4.42%, respectively, compared to those who did not have spacer. Femoral head dose was lower with a 4-field arrangement. Mean differences in left and right femoral head V40% (%) were -6.99% and -10.74%, respectively. Conclusion: We provide a large, novel report of patients treated with IMPT SABR for localized prostate cancer. Four-field IMPT with hydrogel spacer provides significant sparing of rectum and femoral heads without compromising target coverage.

Indexed as

Intensity modulated proton therapyProstate cancerProton therapyStereotactic ablative radiotherapyStereotactic body radiotherapy

Identifiers

PMID38827121
PMCPMC11137510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.